Joseph M Pappachan

Employment

• Countess of Chester Hospital Consultant & Professor
  2025 - Present
• Lancashire Teaching Hospitals NHS Foundation Trust Consultant, Research Lead & Professor
  2018 - 2025
• University Hospitals of Morecambe Bay NHS Trust Consultant in Endocrinology & Metabolism
  2016 - 2018
• Royal Wolverhampton Hospitals NHS Trust Consultant
  2015 - 2016

Education

• Royal College of Physicians FRCP
  2017 - Present
• Royal College of Physicians of the UK, ABCD & Endocrine Society MRCP (Endocrinology & Diabetes)
  2011 - 2016
• Royal College of Physicians Speciality Certificate
  2010 - 2013
• Royal College of Physicians MRCP (UK)
  2003 - 2009
• Coimbatore Medical College MD (General Internal Medicine)
  1998 - 2001
• Calicut Medical College MBBS
  1986 - 1993

Projects & Funding

Projects & funding information is unavailable.

Publications (214)

• From Induction to Maintenance? Rethinking GLP‐1–Based Obesity Pharmacotherapy in the Era of Oral Agents
  Diabetes, Obesity and Metabolism 2026 DOI: 10.1111/dom.70922
  +Save
• Role of Oral Glucagon‐Like Peptide‐1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta‐Analysis of Randomized Controlled Trials
  Obesity Science & Practice 2026 DOI: 10.1002/osp4.70181
  +Save
• Sociodemographic inequalities in onset, mortality and prognosis among patients developing diabetic foot ulcers: a flexible parametric analysis
  2026 DOI: 10.64898/2026.07.06.26355671
  +Save
• Letter to the Editor: Vitamin D deficiency and post-transplant diabetes in kidney recipients - opportunity for risk stratification and intervention
  World Journal of Nephrology 2026 DOI: 10.5527/wjn.122852
  +Save
• Comparative Efficacy and Safety of Tirzepatide in Asian and Non‐Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta‐Analysis
  Endocrinology, Diabetes & Metabolism 2026 DOI: 10.1002/edm2.70291
  +Save
• Low visceral adiposity identifies a metabolically fragile dialysis phenotype with greater glycemic variability
  World Journal of Diabetes 2026 DOI: 10.4239/wjd.120703
  +Save
• Helicobacter pylori and diabetic complications: Stronger evidence for the interlink
  World Journal of Diabetes 2026 DOI: 10.4239/wjd.119178
  +Save
• Glucagon-like peptide-1 receptor agonists in type 2 diabetes: Evidence for disease modification and therapeutic switching
  World Journal of Diabetes 2026 DOI: 10.4239/wjd.116477
  +Save
• Safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, in patients with uncontrolled hypertension: A systematic review and meta-analysis
  Medicine 2026 DOI: 10.1097/MD.0000000000049158
  +Save
• Achondroplasia management in the era of targeted therapies: a meta-analysis of C-type natriuretic peptide analogs
  Journal of the Endocrine Society 2026 DOI: 10.1210/jendso/bvag121
  +Save